Why Invest - Our Story

Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products.

Our strategy is rooted in four strategic imperatives that have remained constant since we began to transform Pfizer in 2011.

Our Strategic Imperatives

1
Innovate & Lead

Improve Pfizer's ability to innovate in biomedical R&D and develop a new generation of high value, highly differentiated medicines and vaccines.

2
Maximize Value

Invest and allocate our resources in ways that create the greatest long-term returns for our shareholders.

3
Earn Greater Respect

Earn society's respect by generating breakthrough therapies, improving access, expanding the dialogue on health care and acting as a responsible corporate citizen.

4
Own Our Culture

Build and sustain a culture where colleagues view themselves as owners, generating new ideas, dealing with problems in a straightforward way, investing in open and candid conversations and working as teammates on challenges and opportunities.

Advancing Our Strategy

2016 Milestones

5
product approvals
6
regulatory submissions
39
compounds in our pipeline advanced
Research & Development
96

assets in our current product pipeline (as of January 31, 2017)

Manufacturing
63

sites worldwide

Global Footprint
96,500

employees (as of December 31, 2016)

across

160

countries

Returned over
$12.3bn

to shareholders through dividends and share repurchases in 2016

Anticipate paying
$1.28

per share in dividends in 2017

Revenue
$52.8bn

Bringing Therapies to Patients that Significantly Improve Their Lives

Pfizer Innovative Health

Strong revenue growth in 2016 and a differentiated and diverse group of products

Oncology

Building a strong capacity in immuno-oncology through partnerships with Merck KGaA and IBM

Vaccines

2 regulatory milestones received from the EMA and the FDA for vaccines to prevent meningococcal disease

Pfizer Essential Health

A strong portfolio and a presence in over 125 countries

Anti-infectives

80 assets in our global portfolio, the largest in the industry

Biosimilars

3 marketed products and 14 biosimilars in the pipeline

Accelerating Patient Impact

250m

doses of Prevenar 13® delivered to Gavi, the Vaccine Alliance, protecting infants in 45 low-income nations

120m+

doses of the antibiotic Zithromax® donated to support the International Trachoma Initiative and fight the world’s leading cause of preventable blindness

250,000+

patients in the U.S. obtained their medicines for free or at substantial discount through Pfizer RxPathways®

Underpinned by our Strong Ownership Culture

Annual global OWNIT! Day

Held fourth annual global OWNIT! Day in April 2016 as colleagues took time to reflect and celebrate Pfizer's OWNIT! culture, with a core focus on accountability.

Colleague Resource Groups (CRGs)

Are open to all colleagues and help drive diversity and inclusion (D&I) throughout our business.

Global Health Fellows program (GHF)

Is an international corporate volunteer program where Pfizer colleagues use their health and business expertise to promote access, quality, outcomes and efficiency of health services for people in need.